Merck & Co. has doubled down on its partnership with Variational AI, striking a deal worth up to $349 million to collaborate on small molecule candidates against two targets. Variational disclosed a ...
VANCOUVER, British Columbia--(BUSINESS WIRE)--Variational AI, the company behind Enki™, an advanced foundation model for small molecule drug discovery, today ...
Variational AI, a Vancouver-based generative artificial intelligence (AI) drug discovery startup, is solving this problem by shifting from screening to generating. At the heart of its technology is ...
The mitochondrion, often referred to as the powerhouse of the cell, plays critical roles in cellular function, making it a prime organelle to target for fundamental studies, metabolic engineering, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback